#covid19 #covidnews #covidtreatment
Researchers Find Ritomavir Boosted Nirmatrelvir Outperforms Molnupiravir in Early COVID 19 Treatment
In an ongoing international study published in The Lancet Infectious Diseases , researchers have found that both molnupiravir and ritonavir-boosted nirmatrelvir accelerate SARS-CoV-2 viral clearance in COVID-19 patients, with ritonavir-boosted nirmatrelvir demonstrating significantly greater antiviral efficacy.
The PLATCOV trial, conducted in Thailand, involved low-risk adult patients aged 18-50 with early symptomatic COVID-19, defined as having symptoms for less than four days. Participants were randomly assigned to one of seven treatment groups, including molnupiravir, ritonavir-boosted nirmatrelvir, and a control group with no study drug.
Among the findings:
Ritonavir-boosted nirmatrelvir demonstrated a remarkable 84% faster viral clearance compared to the control group, while molnupiravir showed a 37% improvement.
In a non-inferiority comparison between molnupiravir and ritonavir-boosted nirmatrelvir, the latter proved superior, with 25% faster viral clearance.
Viral rebound occurred more frequently following nirmatrelvir treatment than in the control or molnupiravir groups.
Molnupiravir was removed from the study platform after reaching a predefined inferiority margin compared to ritonavir-boosted nirmatrelvir.
All reported treatment groups showed no adverse events of grade 3 or worse, or serious adverse events.
Get the latest medical and health news at medicaldialogues.in
Follow us on
Twitter: [ Ссылка ]
Facebook: [ Ссылка ]
Instagram: [ Ссылка ]
LinkedIn: [ Ссылка ]
Website: [ Ссылка ]
